NASDAQ · BMY
Healthcare · Drug Manufacturers - General
$62.25
Down-$1.10 (-1.77%)
Updated Sep 24, 2026, 12:52 AM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BMY closed at $62.25 after 20 trading sessions, down 8.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $62.73 | $63.08 | $62.03 | $62.25 | 15.24M |
| Sep 21, 2026 | $63.09 | $63.395 | $62.62 | $62.62 | 6.84M |
| Sep 18, 2026 | $62.71 | $63.065 | $62.19 | $63.06 | 36.85M |
| Sep 17, 2026 | $64.08 | $64.35 | $62.52 | $62.84 | 12.21M |
| Sep 16, 2026 | $64.07 | $64.385 | $63.22 | $63.60 | 9.45M |
| Sep 15, 2026 | $63.94 | $64.13 | $63.15 | $63.73 | 10M |
| Sep 14, 2026 | $64.59 | $65.29 | $63.91 | $64.10 | 6.9M |
| Sep 11, 2026 | $64.15 | $64.20 | $63.27 | $63.64 | 7.06M |
| Sep 10, 2026 | $64.92 | $64.92 | $63.73 | $63.75 | 6.5M |
| Sep 9, 2026 | $64.57 | $65.05 | $64.2608 | $64.41 | 6.57M |
| Sep 8, 2026 | $65.66 | $65.8931 | $64.395 | $64.69 | 9.52M |
| Sep 4, 2026 | $67.24 | $67.72 | $66.575 | $66.82 | 4.83M |
| Sep 3, 2026 | $68.08 | $68.24 | $66.615 | $68.09 | 6.22M |
| Sep 2, 2026 | $66.815 | $67.73 | $66.7501 | $67.66 | 7.83M |
| Sep 1, 2026 | $67.58 | $68.04 | $66.645 | $66.92 | 6.93M |
| Aug 31, 2026 | $66.25 | $67.199 | $65.9102 | $66.81 | 12.68M |
| Aug 28, 2026 | $66.77 | $66.84 | $66.19 | $66.58 | 5.54M |
| Aug 27, 2026 | $66.59 | $67.47 | $66.20 | $66.95 | 4.67M |
| Aug 26, 2026 | $67.735 | $68.00 | $67.32 | $67.57 | 7.51M |
| Aug 25, 2026 | $66.42 | $68.05 | $66.42 | $67.92 | 7.91M |
The latest Smart Investors Daily articles mentioning BMY.
BMY research
Company profile and research snapshot.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Piper Sandler | Overweight | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo · Sep 18, 2026
Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...
Yahoo · Sep 18, 2026
PRINCETON, N.J., September 18, 2026--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Yahoo · Sep 18, 2026
Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMY.
